Cardiology

Ambu A/S is the global market leader in single-use endoscopy, a category the company created in 2009. The company manufactures and distributes a comprehensive portfolio of single-use (disposable) endoscopic devices and airway management solutions for hospitals, emergency care settings, and training environments. Core product lines include the aScope™ family of flexible endoscopes for pulmonology (bronchoscopy), gastroenterology (gastroscopy), urology (cystoscopy), and ENT applications, as well as rigid and semi-rigid visualization systems. Specialty products include the aScope™ 5 Broncho with color-coded sizing, aScope™ Gastro Large for therapeutic gastroscopy, aScope™ 5 Cysto HD for urology with superior image quality, and the aScope™ 4 Broncho Sampler Set for improved BAL/BW workflow. The company also offers airway management solutions, including the SureSight™ Connect video laryngoscope for intubation and upper airway visualization. Ambu serves multiple clinical specialties: pulmonology, ENT, gastroenterology, urology, neurology, cardiology, and anesthesia. The company has received recognition for technology innovation, earning the 2025 Frost & Sullivan Technology Innovation Leadership Recognition in the European single-use endoscopy industry. All products are single-use, sterile, and designed to eliminate cross-contamination risks associated with reusable instruments. Ambu operates globally with local representatives and maintains both hospital and emergency/training market segments.

Radialogica is a healthtech company specializing in radiation oncology quality management software and services. The company provides tools and services to evaluate, manage, and enhance the quality and safety of radiotherapy treatment planning and delivery for cancer patients. Radialogica operates in two primary business segments: Clinical Trials Services and Clinical Software Tools. In clinical trials, Radialogica partners with pharmaceutical sponsors, biotechnology companies, CROs, and medical device manufacturers to design and implement comprehensive radiotherapy quality assurance programs. Services include development of RT treatment guidelines, collection and aggregation of DICOM-RT treatment plan data, extraction and evaluation of dosimetric parameters, and prospective or retrospective case reviews. The company has processed over 10,000 radiotherapy case submissions across clinical and research projects, operating across 6 continents, 50+ countries, and 600+ clinical sites. Clinical software offerings include SciMoCa™, a Monte Carlo dose calculation and beam model verification platform for dose verification and plan quality evaluation, and fullAccess™, an integrated radiotherapy data display, communication, and analysis platform enabling multi-disciplinary access and sharing of RT data across the continuum of care. These tools have been deployed at over 225 clinical sites worldwide and have impacted quality of care for over 1.5 million patient treatments. Radialogica addresses the significant variability in treatment planning and delivery inherent in radiation oncology through software-enabled prospective quality review and data analytics. The company serves pharma trials, medical registries, payer benefits management, and provider quality benchmarking programs. All services leverage proprietary software tools and technology infrastructure purpose-built for RT data acquisition, processing, and analysis.

ION BEAM APPLICATIONS (IBA) is a global leader in particle accelerator technology, designing, producing, and marketing innovative solutions for cancer diagnosis and treatment, as well as industrial applications including medical device sterilization. The company operates across four primary business segments: Proton Therapy, providing advanced radiation therapy systems for oncology; Dosimetry & Quality Assurance, delivering measurement and verification tools for radiotherapy and radiation protection; RadioPharma Solutions, offering radiopharmaceutical production and diagnostic imaging solutions; and Industrial Solutions, serving sterilization, materials testing, and other industrial sectors. IBA's proton therapy systems represent cutting-edge particle beam technology for precision cancer treatment, while its dosimetry portfolio addresses quality control and safety verification in medical and industrial radiation environments. The RadioPharma segment encompasses cyclotrons, radiochemistry automation, and molecular imaging solutions for PET/SPECT diagnostics. Industrial applications include electron beam and ion beam technology for sterilization of medical devices and pharmaceutical products. The company serves hospitals, cancer centers, diagnostic imaging facilities, and industrial manufacturers globally, with a demonstrated track record of regulatory approvals and international certifications supporting clinical and industrial deployment.

Grifols Egypt for Plasma Derivatives (GEPD) is a public-private joint venture between Egypt's National Service Projects Organization and Grifols, the global healthcare leader. GEPD develops and manufactures plasma-derived medicines to achieve Egypt's clinical self-sufficiency in critical biological therapies. The company has established commercial production of three core plasma derivatives: immunoglobulins (immune globulins), human albumin, and coagulation factors for bleeding disorders. This achievement positions Egypt as the sixth country globally capable of domestic plasma derivative manufacturing. GEPD operates 16 plasma donation centers across Egypt with expansion planned to 20 centers by 2026, supported by European Medicines Agency (EMA) certification enabling export to European markets. The company supplies safe, pharmaceutical-grade plasma-derived medicines to Egyptian public hospitals and health institutions, directly supporting healthcare infrastructure modernization and reducing dependence on imported biological therapeutics.

CytoSorbents, Inc. is a medical technology company specializing in hemoadsorption blood purification therapy. The company develops extracorporeal adsorption devices based on proprietary biocompatible polymer bead technology designed to reduce elevated levels of potentially harmful compounds from whole blood. The primary product, CytoSorb 300®, is an adsorber that complements conventional dialysis approaches and is used in critical care, cardiovascular, liver, and kidney therapeutic areas. CytoSorbents also offers PuriFi, an independent therapy platform enabling standalone CytoSorb® use; ECOS-300CY for ex vivo organ perfusion applications; and VetResQ for veterinary critical-care applications. The company maintains a global presence in over 75 countries and provides clinical support through a team of specialists. Products are CE-marked and available internationally, though CytoSorb 300® and related human therapeutics are not authorized or cleared in the US market. VetResQ is available only in the US. The company positions itself as a trusted partner for advanced blood purification technologies in settings where physiological balance and management of inflammatory or harmful substances is critical.

Uptake Medical Technology Inc. is a San Jose, California-based medical device manufacturer specializing in bronchoscopic thermal vapor ablation (BTVA) systems for pulmonary disease treatment. The company's primary product, InterVapor® (also known as BTVA®), is a non-surgical, non-implant therapeutic system designed to treat severe emphysema and select lung malignancies through vapor ablation technology. The procedure involves delivery of heated, purified water (steam) via a thin bronchoscope inserted through the patient's airway to diseased lung tissue, resulting in tissue ablation and removal via natural healing processes. Treatments typically require less than 15 minutes and can be performed under light sedation in an outpatient bronchoscopy setting. The vapor ablation mechanism targets severely diseased lung regions to improve pulmonary function and breathing capacity in patients with severe emphysema, potentially enhancing quality of life. The company markets its technology as a minimally invasive alternative to surgical lung volume reduction. Note: InterVapor is not currently approved for use in the United States, limiting domestic commercial availability. The company's regulatory and clinical development strategy targets international markets and regulatory approval pathways.

Therakos LLC manufactures the THERAKOS® CELLEX® Photopheresis System, an FDA-approved extracorporeal photopheresis (ECP) device for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) unresponsive to other therapies. The system performs ultraviolet-A (UVA) irradiation of leukocyte-enriched blood in the presence of 8-methoxypsoralen (8-MOP), with co-administered pharmaceutical UVADEX® (methoxsalen) sterile solution. The company provides a complete therapeutic platform including the photopheresis system hardware, consumables, operator training through the Therakos Institute, and comprehensive customer support services branded as Therakos Total Care. The system is designed for use in clinical settings where standard medical emergency equipment and volume management capability are available. Following acquisition by CVC, certain operations continue under transition services agreement with Mallinckrodt Pharmaceuticals. Therakos markets primarily to hematology-oncology centers, dermatology departments, and specialized treatment centers managing CTCL patients. The company maintains dedicated business manager support and professional education programs for treating physicians and clinical staff. Product indications and contraindications are clearly defined with specific patient selection criteria and comprehensive safety protocols documented in the operator's manual and UVADEX prescribing information.

Fasikl Inc. is a neurotechnology company developing AI-based therapeutic devices for neurological conditions. The company's flagship product, Felix NeuroAI™ Wristband, is a non-invasive wearable device that has received FDA clearance for the treatment of essential tremor. Felix operates through advanced AI technologies that decode and modulate neural signals, delivering all-day symptomatic relief without surgery or medication. The device represents a breakthrough in AI therapeutics, combining cloud-based artificial intelligence with real-time neural signal processing. Fasikl also develops the Fasikl-X™ Nerve-Computer Interface platform for broader neural interfacing applications. The company has invested over 20 years of R&D in neural signal processing and AI-driven treatment modalities. Products are designed for direct patient use and clinical settings, with support for both individual patients and healthcare providers. FDA clearance indicates regulatory approval for the Felix device as a Class II or higher medical device. The company targets essential tremor patients and related neurological indications, positioning itself at the intersection of wearable medical devices, neurotechnology, and artificial intelligence therapeutics.

Nyxoah is a medical technology company specializing in the development and commercialization of innovative solutions for obstructive sleep apnea (OSA) treatment. The company's flagship product is the Genio® system, a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy designed to treat OSA, the world's most common sleep-disordered breathing condition. OSA affects approximately 936 million people globally between ages 30–69, with 425 million suffering from moderate to severe cases requiring treatment. Left untreated, OSA is associated with significant morbidity and mortality, including doubled stroke risk, five-fold increased cardiovascular mortality, and a 140% increased risk of heart failure. The Genio® system offers an alternative to traditional continuous positive airway pressure (CPAP) therapy, addressing the substantial unmet clinical need in sleep medicine. Nyxoah is actively expanding operations and commercializing its lead solution across multiple markets. The company maintains a focus on clinical evidence and patient outcomes in treating this major sleep-disordered breathing condition with significant cardiovascular and systemic implications.

Stevanato Group is a global leader in integrated solutions for the pharmaceutical and biotechnology industries, with over 75 years of expertise in drug containment, drug delivery systems, and in-vitro diagnostic solutions. The company manufactures glass primary packaging (vials, cartridges, syringes) for pharmaceutical products, pre-filled syringe systems including the Alba® platform for biologics, and specialized injection needles such as the sTW (Special Thin Wall) needle for high-viscosity drugs. The Aidaptus® autoinjector platform provides flexible drug delivery mechanisms. Stevanato operates advanced manufacturing facilities in Fishers, Indiana (US hub for North American customers), Monterrey (Mexico), and Zhangjiagang (China). The company provides visual inspection systems, secondary packaging solutions, assembly equipment, glass-converting automation, and analytical testing services for container-closure systems and drug interactions. Products serve development, clinical, and commercial stages of the drug lifecycle. The group maintains ISO certifications and regulatory compliance across major markets and offers contract manufacturing competencies integrated with proprietary technologies. Recent innovations include Digital Holographic Microscopy (DHM®) for silicone coating characterization and advanced syringe formulations for IV drug delivery compatibility.

Esaote S.p.A. is a global medical imaging manufacturer founded in the early 1980s, headquartered in Italy with significant operations in the United States (Fishers, IN). The company specializes in ultrasound systems, magnetic resonance imaging (MRI), and healthcare IT solutions. Their product portfolio includes advanced ultrasound platforms such as the MyLab series (MyLab E85 GTS, MyLab C30 GTS) featuring proprietary technologies like PAM (Photoacoustic Microscopy) for precision imaging across multiple clinical applications including cardiology, urology, and interventional radiology. Esaote also develops intraoperative MRI systems, exemplified by the I-Genius platform for neurosurgery. The company offers comprehensive healthcare IT and enterprise imaging solutions integrated with clinical workflows for prevention, diagnosis, therapy, and follow-up. Esaote serves hospitals, diagnostic imaging centers, and specialty practices globally. The company holds relevant regulatory certifications and maintains robust R&D capabilities focused on clinical needs and market trends. Esaote emphasizes customer care, technical support, and equipment performance optimization. The organization has achieved UNI/PdR 125:2022 gender equality certification and maintains commitment to sustainability and ESG principles. Recent strategic partnerships, such as with Schiller Americas for cardiology imaging expansion, reflect the company's growth trajectory in the North American market.

Riverpoint Medical is a Portland, Oregon-based medical device manufacturer founded in 1990, specializing in the design, development, and manufacturing of advanced surgical fibers, implantable textiles, and regenerative technologies. The company serves orthopedics, sports medicine, cardiovascular care, wound closure, veterinary, and dental markets with bioresorbable and non-absorbable sutures, custom fibers, and implantable materials. Operating with approximately 50 employees and $7.4 million in annual revenue, Riverpoint Medical combines in-house technology and rapid innovation capabilities with comprehensive services including custom design, private labeling, manufacturing, and regulatory support. The company positions itself as a full-service partner enabling healthcare device manufacturers and suppliers to efficiently bring surgical fiber and textile-based solutions to market.

Corvascular Diagnostics, LLC manufactures the VasoGuard® Peripheral Vascular Testing System, a comprehensive family of diagnostic devices for non-invasive vascular assessment. The product line includes five modular configurations (V2, V4, V6, V8, V10) designed to support varying clinical testing protocols, from basic screening to advanced multi-parameter diagnostics. Each system integrates pressure channel monitoring (2–10 channels), photoplethysmography (PPG) probes (2–5 units), and Doppler ultrasound capabilities (8 MHz and/or 4 MHz), coupled with medical-grade touchscreen interfaces and height-adjustable carts. All units are manufactured in the USA with on-site support and service. The company provides a 5-year bumper-to-bumper warranty and optional accidental damage coverage (ADC), with on-site training included as standard. The VasoGuard line serves peripheral vascular diagnostic needs in hospital systems, vascular labs, and outpatient clinics. Hardware upgradability between models allows clinical facilities to expand testing capacity. The company emphasizes clinical accuracy, state-of-the-art pressure monitoring, and Doppler envelope technology for reliable patient assessment.

MeKo Manufacturing e.K. is a contract manufacturer of precision medical components and implants for the interventional and surgical device industry. Founded in 1995, the company pioneered stent manufacturing and is now among the largest contract manufacturers of medical components globally. MeKo specializes in laser cutting, laser welding, and advanced processing of materials including stainless steel (316L, 316LVM), cobalt alloys (L605, Phynox, MP35N), nitinol (NiTi), magnesium alloys (Resoloy®), nickel-free alloys (Vasculoy®), and polymers (PolyMediX®, PLLA, PGA). The company manufactures implants for cardiology, neurology, radiology, ophthalmology, and urology applications, with product lines including metal stents, NiTi stents, hypotubes, retrieval baskets, bone nails, heart valve frames, orthopedic devices, surgical instruments, microcomponents, and drug-delivery balloon catheters. Manufacturing capabilities include CAD/CAM design, precise laser cutting (tolerances below ±5 μm), laser welding, mechanical processing, heat treatment, shape setting, electropolishing, 3D metal printing, polymer coating, marker crimping, and rapid prototyping. The company operates ISO-certified quality management with 100% visual inspection using over 100 specialized high-end microscopes and maintains ISO 8 cleanrooms (Class 100,000). MeKo offers finite element analysis (FEA) simulation services, prototype-to-series production capabilities, and operates 24/7 manufacturing. The company maintains facilities in Germany (Sarstedt, near Hannover), the USA (Bloomington, Minnesota), California, and Costa Rica.

Bridge to Life Ltd. is a biotechnology company based in Northbrook, Illinois, specializing in organ preservation, perfusion, and revitalization solutions for transplantation. The company develops and manufactures preservation fluids, hypothermic oxygenated perfusion (HOPE) systems, and related consumables for organ procurement organizations (OPOs) and transplant centers globally. Key products include the Belzer UW® cold storage solution and machine perfusion solution (gold-standard preservation fluids), VitaSmart™ hypothermic oxygenated perfusion system (FDA DE NOVO cleared for HOPE), EasiSlush® sodium chloride solution for slush preparation, and French-sized cannula tubing for organ procurement. The company supports the transplant community with preservation technologies designed to improve organ viability, extend preservation windows, and enhance recipient outcomes. Bridge to Life maintains partnerships with leading transplant institutions and conducts clinical research, including the Bridge to HOPE trial evaluating VitaSmart™ in liver transplantation.

MagnetTx Oncology Solutions is a medical device manufacturer specializing in advanced radiotherapy systems for cancer treatment. The company's flagship product is the Aurora-RT, a next-generation LINAC-MR (linear accelerator-magnetic resonance) hybrid system that integrates high-quality MR imaging with a 6 MV linear accelerator for targeted cancer radiation therapy. The Aurora-RT combines pre-treatment MR imaging for precise patient alignment with real-time MR imaging during beam delivery, enabling adaptive radiotherapy and tumor tracking. Key advantages include minimal electron return effect, superior soft-tissue contrast compared to traditional Cone Beam CT guidance systems, and concurrent imaging during treatment delivery. The device features an open-concept design, modular treatment table capabilities, and helium gas cooling (eliminating liquid helium dependency). Aurora-RT is FDA-approved, CE-marked, and UKCA-approved for use in the United States, European Union, and United Kingdom markets. The system is designed with patient comfort and safety as primary considerations, and operates as an open-source platform compatible with multiple treatment planning systems. MagnetTx serves cancer centers and radiotherapy facilities requiring advanced imaging-guided radiation oncology capabilities.

Starboard Medical is a US-based, woman co-owned medical device manufacturer specializing in temperature management products and thermistor sensor technologies. The company produces a range of temperature probes and sensors including esophageal stethoscopes, general-purpose temperature probes, skin temperature sensors, and tympanic temperature sensors for clinical monitoring applications. Beyond branded products, Starboard offers comprehensive OEM and contract manufacturing capabilities including insert molding, injection molding, dip molding, tubing extrusion, and full packaging services. The company serves medical device OEMs and healthcare facilities requiring specialized temperature sensing solutions and manufacturing partnerships.

Alpha-Omega Services, Inc. (AOS) is a specialized contract manufacturer and supplier of radiation therapy products and radioactive material handling solutions, operating since 1973. The company serves radiation therapy OEMs, industrial entities, and research organizations with sealed contract manufacturing of Iridium-192 (Ir-192) HDR brachytherapy sources for medical device manufacturers, NRC-certified Type B transport casks for secure shipment of radioactive materials (including the AOS-100 series featuring trunnions and dual-end lids), and expert consulting on complex radioactive material projects and regulatory compliance. AOS holds multiple industry licenses and NRC certifications, ensuring compliance with nuclear regulatory standards. The company emphasizes over 50 years of manufacturing excellence, regulatory compliance, quality control, and competitive pricing for OEMs, distributors, and healthcare providers. AOS provides sealed source manufacturing, radioactive material (RAM) handling and packaging, and specialized consulting for medical device manufacturing and regulatory approval processes.

Theragenics Corporation is a global specialty medical device company founded in 1981 by physicists from Georgia Institute of Technology, headquartered in Buford, Georgia. The company specializes in commercial-scale radioisotope manufacturing and low-dose-rate (LDR) brachytherapy seeds for cancer treatment, with a vertically integrated operation managing isotope production, manufacturing, and global logistics. Theragenics operates a 134,000 sq ft radioisotope production facility with 14 cyclotrons enabling large-scale isotope production for therapeutic and diagnostic radiopharmaceuticals. The company's flagship brachytherapy products include TheraSeed® Palladium-103, AgX100® Iodine-125, and Cesium-131 seeds, along with innovative delivery systems such as preloaded needle trays, eye plaques, C20™ cartridges, AnchorSeed® encapsulated seeds, and stranded configurations. Theragenics also provides contract manufacturing services for radiopharmaceuticals and operates subsidiary companies offering interventional radiology and vascular surgery solutions. With over 40 years of excellence, the company has treated more than 271,000 patients worldwide and serves physicians and providers in over 40 countries, emphasizing precision, quality, and patient-centric innovation in minimally invasive cancer therapies.

Furuno Electric Co., Ltd. is a diversified manufacturer of marine navigation, positioning, and medical equipment. Primary business focuses on marine electronics for recreational boats, merchant marine, fishing vessels, and workboats, including fish finders, sonar systems, multi-beam sonars, marine radar, GPS/GNSS chart plotters, autopilots, and integrated navigation displays. The company also manufactures GPS/GNSS receiver chips and modules for positioning and timing applications, including 5G network infrastructure. In the medical segment, Furuno produces clinical chemistry analyzers and ultrasound bone densitometers for diagnostic and monitoring applications. The company provides navigational equipment training and coastal monitoring systems. Furuno operates with advanced capabilities in GNSS timing technology, autonomous navigation solutions, cyber security, and remote monitoring platforms. The organization serves global maritime markets and has expanded into industrial positioning and healthcare diagnostics. Products meet international maritime standards and regulatory requirements for marine equipment.

Ergotron Inc. is a manufacturer of ergonomic healthcare and workspace solutions with over 40 years of operational history. The company specializes in mobile medical carts, monitor mounts, standing desks, workstations, and charging systems designed for healthcare facilities, offices, educational institutions, and industrial environments. Key product lines include the Mosaic ultra-configurable workstation with RhythmConnect fleet management software, the CareFit Combo modular care cart, and the StyleView medical cart line. Ergotron offers specialized telemedicine carts, light-duty and full-featured medical workstations, and procedure-specific cart configurations. The company manufactures monitor mounting systems (desk, wall, and multi-monitor configurations), charging cabinets and carts for Chromebooks, iPads, laptops, and tablets, and standing desk solutions. Products serve healthcare delivery, clinical workstations, medication management, and point-of-care computing environments. The company maintains a global presence with participation in major medical and healthcare trade shows (DMEA, EXPOSANITA, SAMTIT, HKTDC Medical Fair, Digital Health Festival). Ergotron's design philosophy emphasizes human-centered ergonomics and movement-enabled workspaces to reduce caregiver strain and improve workflow efficiency in clinical settings. The company provides workspace assessment tools, ergonomic planning resources, and integrated fleet management capabilities through RhythmConnect for healthcare IT asset management.

Accuray Incorporated is a global leader in radiation oncology and radiosurgery systems. The company manufactures advanced treatment platforms designed to deliver precise radiation therapy across a full spectrum of patient needs, with 479+ systems installed in 33+ countries. Accuray's primary product lines include the CyberKnife® S7™, a robotic stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system featuring AI-driven real-time motion synchronization for tumor treatment anywhere in the body, and the Radixact® system, which combines integrated 3D kVCT and megavoltage CT (MVCT) imaging for image-guided intensity-modulated radiation therapy (IG-IMRT) and 3D conformal radiation therapy (3DCRT). Both systems are designed to improve treatment precision, reduce workflow complexity, and enhance patient outcomes. Accuray serves oncology centers, hospitals, and specialized radiotherapy facilities globally. The company emphasizes quality of care, efficiency of workflow, and clinician confidence through continuous innovation. Over 31% of system components are sourced from U.S. suppliers. Accuray supports its installed base through comprehensive training programs, the AEx® peer community platform for user education and experience-sharing, and dedicated service and reimbursement support. The company operates in the high-stakes cancer treatment market, addressing complex cases including prostate, lung, brain, and other tumor types.

RefleXion Medical develops biology-guided radiotherapy (BGRT) systems for cancer treatment. The company's flagship product, the RefleXion X1 machine with SCINTIX autonomous radiotherapy, combines PET (positron-emission tomography) imaging with linear accelerator (LINAC) radiation therapy to enable real-time tumor tracking and treatment delivery. SCINTIX detects biological signals emitted by cancer cells after radiopharmaceutical injection and uses this information to autonomously guide radiation beams to tumors in motion, potentially reducing dose to surrounding healthy tissue. The system is FDA-cleared for treatment of lung and bone tumors, including primary and metastatic disease at any stage. In addition to SCINTIX therapy, the RefleXion X1 platform delivers conventional radiotherapy modalities including SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), and IMRT (intensity-modulated radiation therapy) for solid tumors throughout the body. The platform is designed to fit standard radiotherapy vaults with minimal shielding modifications and is compatible with third-party immobilization devices and existing contouring tools. Founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri, RefleXion has secured over $400 million in venture financing and employs more than 250 people. Leadership includes Todd Powell (President and CEO, formerly of Elekta) and Martyn Webster (CFO). SCINTIX therapy has achieved Medicare reimbursement through multiple Medicare Administrative Contractors (MACs), supporting adoption in freestanding cancer centers and hospital outpatient departments. The company targets oncology departments, cancer centers, and radiation therapy facilities.

Forj Medical is a global contract design and manufacturing organization (CDMO) specializing in advanced medical device development and high-volume manufacturing. The company operates 450,000+ square feet of manufacturing space across six global facilities (U.S., Costa Rica, Singapore, Indonesia) and assembles 250+ million devices and components annually. Core competencies include electromagnetic sensors and navigation systems, surgical energy systems, fluid and gas management solutions, optical systems, stimulation and active wearables, and consumables and components. Forj Medical provides end-to-end services from concept and full medical device system development through commercialization, including custom electromechanical system design, design for manufacturing (DFM), design for automation and scale, custom prototyping, and process and test development. Manufacturing capabilities are vertically integrated, encompassing PCBA manufacturing, precision molding, cable assembly, cleanroom operations, polymer and metal 3D printing, and automation. The company maintains ISO 13485 certification and holds five FDA Establishment Registrations. Quality management systems include robust QMS, traceability protocols, risk management, and audit readiness. Supply chain and operational services include supply chain management, service and maintenance, sustaining engineering, packaging and shipping, and international logistics. Clients span Fortune 500 medical device manufacturers and emerging medtech companies. The organization combines 4+ million combined hours of medical device engineering expertise across its portfolio.

Ypsomed AG is a Swiss-based leading developer and manufacturer of self-injection systems for liquid medications, with over 40 years of innovation in drug delivery technology. The company specializes in customized injection platforms for pharmaceutical and biotech partners, including disposable pens, autoinjectors (such as YpsoMate), and wearable on-body devices. Ypsomed operates a global manufacturing network with facilities in Burgdorf, Schwerin, Changzhou, and Solothurn, employing over 2,000 people. The company provides comprehensive services spanning device development, clinical trial support (Clear-to-Clinic program), human factors engineering, and digital health integration. Products are designed for subcutaneous self-administration of therapeutics across chronic disease categories including diabetes, autoimmune conditions, and specialty biologics. Ypsomed emphasizes sustainable manufacturing practices, having achieved LEED Platinum certification at its Changzhou facility, and maintains 100% renewable energy sourcing for operations.

Fine Surgical Instruments, Inc. is a leading manufacturer and distributor of precision surgical instruments based in Hempstead, New York. The company supplies the global medical industry with an extensive range of high-quality surgical instruments across multiple specialties. Their comprehensive product portfolio includes diagnostic instruments, scalpels, scissors, forceps, needle holders, retractors, suturing instruments, and specialty tools for ophthalmology, ENT, gynecology, obstetrics, orthopedics, cardiology, urology, thoracic, neurosurgery, and bariatric procedures. Fine Surgical serves hospitals, surgical centers, and medical practitioners worldwide, offering both standard surgical instruments and specialized equipment for various surgical disciplines. The company provides an online catalog for procurement efficiency and maintains dedicated domestic and international sales teams.

STORZ MEDICAL AG is a Swiss-based world leader in non-invasive shock wave therapy systems and lithotripters, established in 1987. The company designs and manufactures high-precision medical devices for Extracorporeal Shock Wave Lithotripsy (SWL), Extracorporeal Shock Wave Therapy (ESWT), and Extracorporeal Magnetotransduction Therapy (EMTT). Its products serve multiple clinical disciplines including urology (kidney and ureteral stone treatment), orthopedics and sports medicine (musculoskeletal disorders), cardiology (Cardiac Shock Wave Therapy for myocardial revascularization), neurology (Transcranial Pulse Stimulation for Alzheimer's disease), dermatology, and veterinary medicine. The MODULITH® SLX-F2 is FDA-approved for pediatric kidney stone therapy in the USA. With over 100,000 installed systems in 130+ countries, STORZ MEDICAL offers both focused and radial shock wave modalities, complemented by vibration therapy (V-ACTOR®) and integrated software solutions. All devices carry CE, FDA, and MDSAP certifications.

RAUMEDIC AG is a Germany-based (Helmbrechts) manufacturer specializing in polymer-based medical devices and pharmaceutical components. The company develops and manufactures tubing systems, catheters, cannulas, syringes, and infusion sets for cardiosurgery, cell and gene therapy, drug delivery, enteral feeding, infusion therapy, neuromonitoring, ophthalmology, orthopedics, and traumatology applications. RAUMEDIC operates an in-house online shop for single-use bioprocess equipment and offers comprehensive services including material expertise, product design, prototyping, manufacturing, and regulatory support (product registration guidance). The company maintains competencies across material development, product concept design, precision prototyping, and multiple manufacturing technologies. RAUMEDIC serves hospitals, pharmaceutical manufacturers, and biotech firms globally, with demonstrated commitment to sustainability including development of low-carbon footprint medical consumables. The company is headquartered in Germany with operations indicated in multiple markets.

West Coast Surgical is a contract manufacturer and design-to-production partner specializing in surgical devices and instrumentation. With over 20 years of experience, the company focuses on cardiovascular, neuro, and spine instruments, offering end-to-end services from concept development through finished device manufacturing. Core capabilities include device design and development, contract manufacturing, prototyping, and design for manufacturing (DFM). The company operates FDA-registered facilities in Half Moon Bay, California and Houston, Texas, equipped with advanced machining capabilities including CNC milling (5-axis), Swiss lathes, wire EDM, heat treating, and inspection/quality control systems. West Coast Surgical serves both established medical device companies and emerging ventures, with expertise in regulatory compliance and quality system implementation.

coVita is a leader in breath analysis and respiratory diagnostic equipment, founded in 1976 and headquartered in Santa Barbara, CA. The company manufactures FDA-cleared breath monitoring devices for clinical and occupational health applications. Their product portfolio includes: ToxCO®, a breath carbon monoxide monitor for CO poisoning detection and management; NObreath®, a FeNO (fractional exhaled nitric oxide) monitor for airway inflammation assessment in asthma diagnosis and management; Smokerlyzer® series, which measures exhaled carbon monoxide to support smoking cessation programs; and Gastrolyzer® devices for non-invasive hydrogen and methane breath testing in gastrointestinal disorder diagnosis. All primary product lines carry FDA 510(k) clearance. The company operates manufacturing and R&D facilities in Santa Barbara and maintains a USA Service Center and Customer Service & Sales Team in The Woodlands, TX. Clinical applications span pulmonology, gastroenterology, occupational health, and smoking cessation programs. Devices are designed for rapid, non-invasive patient testing in clinic and office-based settings.

Coghlin Companies, Inc. is a fourth-generation contract manufacturing and engineering services company (founded 1885) specializing in the design, engineering, and precision manufacturing of complex capital equipment and medical devices. Based in Westborough, Massachusetts, with ~480 employees and $159.9M annual revenue, the company serves medical life sciences, semiconductor, robotics, and industrial sectors. Core capabilities include product engineering, design for manufacturability (DFM), prototyping, printed circuit board assembly, total system integration, and global supply chain fulfillment. Notable achievements include manufacturing 10,000 ventilators during COVID-19. Coghlin operates both industrial (Columbia Tech) and medical (Cogmedix) divisions, providing end-to-end commercialization services from concept through scalable manufacturing and aftermarket support.

Millar LLC is a medical sensor technology company specializing in MEMS (microelectromechanical systems) pressure sensors and related sensing solutions for medical devices and industrial applications. Founded in 1969, Millar has over 55 years of expertise in high-fidelity pressure measurement for acute and chronic monitoring. The company's core product portfolio includes acute pressure sensors (minimally invasive, high-accuracy measurement), chronic pressure sensors (TiSense implantable technology for up to 10-year monitoring in titanium housings), ISFET pH sensors, electrical conductivity (EC) sensors, oxidation-reduction potential (ORP) sensors, temperature sensors, and volume measurement solutions. Millar operates as a Contract Design and Manufacturer (CDMO) providing end-to-end sensor integration services from discovery and proof of concept through prototyping, manufacturing development, design validation, clinical trials, and device commercialization. The company holds ISO 13485 certification and operates an ISO Class 7 clean room facility supporting FDA-approved medical device production. Millar also operates a pure-play MEMS microfoundry for custom sensor fabrication. Primary markets include cardiovascular monitoring, hemodynamic pressure measurement, and OEM medical device integration. The company serves both medical device manufacturers requiring sensor integration and industrial customers requiring environmental and process monitoring solutions. Regulatory credentials include experience with FDA 510(k) pathways and clinical trial support.

Saladax Biomedical, Inc. is a biotechnology company specializing in therapeutic drug monitoring (TDM) assays for psychiatry and oncology. The company develops and manufactures rapid blood-level measurement tests that optimize drug dosing for essential medications prescribed by psychiatrists and oncologists. Key products include the My5-FU Assay for monitoring 5-Fluorouracil chemotherapy (Health Canada approved, May 2024) and MyCare™ Insite for clozapine monitoring with point-of-care testing capabilities, delivering results in hours rather than days. Saladax supports personalized medicine initiatives through companion diagnostics and clinical trial collaborations with pharmaceutical partners. The company's TDM solutions enable clinicians to confirm medication adherence, optimize dosing regimens, and reduce toxicity risks, improving patient outcomes in psychiatric and oncological care. International distribution partnerships expand access across multiple regions.

Tensentric is an ISO 13485:2016 certified engineering and manufacturing firm specializing in design, development, prototyping, and volume production of medical devices, in-vitro diagnostics (IVD), and life sciences systems. Founded in 2009 and headquartered in Boulder, Colorado, the company employs 83–96 engineers and scientists, many with over 20 years of experience across electromechanical systems, microfluidics, bioprocessing, and human factors optimization. With over 300 completed development projects and 75+ patents, Tensentric delivers turn-key system design from concept through volume manufacturing. Core competencies include custom-engineered instruments and consumables, point-of-care diagnostic platforms, cell and gene therapy bioprocessing equipment, and complex integrated systems for sample handling, biochemical analysis, and detection. Services encompass design and development, human factors and use-safety engineering, new product introduction (NPI), and dedicated manufacturing. Clients include Medtronic, BD, Philips, Johnson & Johnson, Stryker, and other major medtech OEMs. In 2022, the firm received strategic investment from GenNx360 Capital Partners to expand manufacturing and business development capabilities.

DxTx Medical Inc. is a Pittsburgh, PA-based medical device manufacturer specializing in endorectal imaging coils and radiation therapy devices for prostate MRI diagnostics and treatment planning. The company designs and manufactures high-resolution endorectal coils compatible with GE 1.5T and 3.0T MRI scanners (Artist and Voyager models), as well as interface devices and the Pro-Tx endorectal balloon system. These devices enhance tissue resolution and signal-to-noise ratio in prostate imaging, enabling radiologists and urologists to improve diagnostic accuracy and treatment planning for prostate cancer. DxTx Medical serves imaging centers, urology departments, and radiation therapy facilities. The company provides comprehensive support including product repairs, maintenance, servicing, and warranty protection to keep devices operational. Products are designed for clinical use in high-resolution prostate MR imaging and radiation therapy planning, supporting better patient outcomes through enhanced diagnostic visualization.

CMR Naviscan Corporation manufactures and markets molecular breast imaging (MBI) systems for breast cancer detection and diagnosis. The company's primary product is the lumaGEM system, a gamma imaging platform designed for screening and diagnostic applications in breast imaging. The lumaGEM system is used as a primary screening option, secondary screening modality for high-risk patients and those with dense breast tissue, and for adjunct evaluation of occult primary breast carcinoma and equivocal conventional imaging findings. The company also offers the Solo II imaging platform and Stereo Navigator navigation system. Clinical data presented on their site demonstrates increased invasive cancer detection rates, reduction of benign biopsies in women with dense breast tissue compared to other modalities, and lower cost per cancer detected when MBI is added to screening mammography. The lumaGEM system is positioned to address the significant clinical challenge of dense breast tissue, where both cancer and fibroglandular tissue appear white on conventional mammography, reducing sensitivity. CMR Naviscan's solutions are used by radiologists and breast cancer centers for both screening and diagnostic purposes, with published evidence supporting efficacy in early cancer detection. The company participates in major industry conferences such as the Society of Breast Imaging symposium.

Mirion Technologies is a global provider of radiation detection, measurement, and safety solutions serving nuclear power operations, medical imaging and cancer care, occupational dosimetry, and environmental radiochemistry. The company specializes in radiological instrumentation, personal and area dosimetry products, radiation survey monitoring equipment, and supervisory software platforms. Key product lines include the Vital® Supervision platform (centralized radiological instrumentation management), CSPevo® Probe Family (portable radiation survey monitoring), Instadose®VUE (wireless personal dosimeters), and FRAM isotopic analysis systems. Mirion serves nuclear utilities, medical oncology centers, radiopharmaceutical manufacturers, research institutions (including the IAEA), and government agencies including NASA. The company provides training courses in radiation measurement and equipment operation, hosts industry conferences (Mirion Connect), and maintains service and support capabilities across multiple markets. Recent acquisitions and partnerships (Paragon Energy Solutions, Certrec) expand capabilities in nuclear licensing and infrastructure. Mirion's dosimetry products are used by healthcare workers and space program personnel (NASA Artemis missions).

Cooler Heads Care, Inc. manufactures the Amma™ Scalp Cooling System, an FDA-cleared medical device designed to reduce chemotherapy-induced hair loss in cancer patients. The system is intended for adults 21 and older undergoing treatment for solid tumors. Amma consists of four integrated components: a custom-fitted cooling wrap that delivers chilled solution to the scalp, a neoprene compression strap, a compression cap for secure fit, and a portable cooling unit that circulates and maintains optimal temperature. The device operates by cooling the scalp before, during, and after chemotherapy administration, thereby reducing chemotherapy drug penetration to hair follicles and supporting hair preservation and regrowth. Treatment protocol requires cooling initiation 30 minutes before chemotherapy and continuation for 2–3 hours post-infusion. The Amma system is distinguished by its portability, allowing patients mobility throughout infusion centers, and features a custom-fitted wrap requiring no mid-session adjustments. The company provides comprehensive patient and clinical staff support through a dedicated customer care team, training tools, and clinical guidance. Cooler Heads has received backing from established accelerators and research institutions including StartX, Endless Frontier Labs, and the NIH National Cancer Institute, and is recognized by MedTech Innovator and the California Technology & Innovation Program. The product addresses multiple medical and psychosocial contraindications and requires provider prescription and infusion center availability.

DoseOptics manufactures BeamSite, an FDA-cleared Cherenkov imaging system that captures real-time video visualization of radiation therapy dose delivery to patients during treatment. BeamSite is the first clinical system to provide direct visual verification of radiotherapy beam placement and dose delivery by imaging Cherenkov light emissions. The company offers two product lines: BeamSite for clinical use in radiation oncology departments, and BeamSite Research for laboratory and research applications. By enabling clinicians to visually verify radiation therapy in real time, BeamSite supports treatment quality assurance, reduces delivery errors, and enhances patient safety. Clinical evidence demonstrates that visualization can identify suboptimal treatments that would otherwise go undetected. DoseOptics also partners with Vision RT to offer DoseRT, a Cherenkov imaging system integrated with Surface-Guided Radiation Therapy (SGRT) technology. The company serves radiation oncologists, medical physicists, radiation therapists, hospital administrators, and research institutions.

Evergen is a global Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine and custom biomaterial solutions. Founded in 1998 and headquartered in Alachua, Florida, the company designs, develops, and manufactures tailored allograft and xenograft biomaterial products for OEM partners across multiple surgical specialties. With manufacturing facilities in the United States, Europe, and New Zealand and over 850 employees, Evergen delivers end-to-end CDMO services with deep clinical expertise in plastic and reconstructive surgery, sports medicine, orthopedics, neuro/spine surgery, and cardiac surgery. The company has achieved over 181 FDA 510(k) clearances, 721+ market authorizations, and supported more than 73 million implants worldwide. Evergen emphasizes a patient-first approach and collaborates closely with customers to develop innovative, scalable regenerative solutions that promote healing, accelerate recovery, and enhance patient outcomes.

CG MedTech USA, Inc. (Irvine, California) is a specialized manufacturer of orthopedic and spinal implant technologies serving Ambulatory Surgery Centers (ASCs), hospitals, and surgical specialists. The company offers a comprehensive portfolio spanning spinal implants, trauma fixation systems, sports medicine devices, pain management solutions, and biologic products. With a commitment to value-based pricing, CG MedTech provides competitively priced, quality-assured implants that challenge market premiums while maintaining rigorous R&D investment and industry compliance. The company serves manufacturers, distributors, surgeons, hospitals, and patients with a focus on clinical outcomes and procurement efficiency. Global operations include headquarters in South Korea and dedicated U.S. sales and R&D centers, positioning CG MedTech as a reliable partner for cost-effective orthopedic solutions without compromising device quality or performance.

HillTek LLC is the United States distributor of HiToP® (High-Tone Therapy), an advanced, patented cellular optimization technology developed and manufactured by gbo Medizintechnik AG in Germany since 1969. HiToP® is a Class II medical device (FDA-cleared) and CE-marked under European medical device regulations, backed by over 30 published peer-reviewed scientific papers. The technology uses patented high-frequency modulated electrical energy to optimize cellular voltage, promote mitochondrial energy production, and enhance cellular diffusion, supporting whole-body and localized therapeutic applications. HiToP® is non-invasive, hands-free, and clinically indicated for functional medicine (pain reduction and chronic illness management), wellness and longevity (cellular rebalancing and restoration), and sports medicine (recovery acceleration and performance optimization). The product line includes three models: HiToP® 1touch (single-channel, portable, up to 5000 mW), HiToP® 2touch (dual-channel, scaled efficiency), and HiToP® 4touch (four independent channels for advanced clinical environments). All devices deliver comparable power to high-power laser therapy while remaining gentle and well-tolerated, typically producing only subtle tingling sensations. HiToP® holds 3 international patents and is designed for healthcare, wellness, and performance professionals in functional medicine clinics, integrative medicine practices, athletic teams, and boutique wellness facilities. Manufacturing and design are entirely German-engineered.

THOR Photomedicine Ltd is an ISO 13485:2016-certified medical device manufacturer based in Amersham, England, specializing in photobiomodulation (PBM) therapy equipment—also known as low-level laser therapy (LLLT). Founded in 2007, the company designs and manufactures advanced laser and LED light therapy systems, treatment probes, and control units for clinical and therapeutic applications. THOR serves over 5,000 customers across more than 70 countries, including hospitals, clinics, sports franchises, and veterinary practices. The company holds FDA, CE, TGA, and NATO clearance and is listed on the US GSA and eCAT schedules for government procurement. THOR's flagship product, the LX2.3 Photobiomodulation System, delivers targeted light therapy for pain relief, tissue repair, and inflammation reduction across indications including musculoskeletal pain, oral mucositis, tendinopathies, joint conditions, wound healing, and sports medicine. The company is backed by extensive clinical research partnerships with leading universities and has supported over 1,700 randomized controlled trials and 11,000+ publications. THOR provides comprehensive training courses globally and maintains a commitment to establishing photobiomodulation as standard care in hospital departments by 2030.

De Soutter Medical Limited is a leading British manufacturer of powered surgical instruments and medical devices based in Aylesbury, England. Founded in 1990, the company specializes in high-performance, cost-effective surgical power tools for orthopedic, trauma, cardiothoracic, neuro-ENT, and plastic surgery applications. The product portfolio includes over 800 items spanning modular and dedicated instruments powered by battery, electric, or pneumatic options. Key product lines include ORTHODRIVE® systems for large bone surgery, OSTEODRIVE® II for extremity procedures, TRAUMADRIVE™ for trauma applications, hekaDrill™ for neuro-ENT work, arthrodrive® shaver systems for arthroscopy, sternudrive™ sternum saws for cardiothoracic procedures, and dermadrive™ for plastic surgery. The company also manufactures cast removal systems (CleanCast™ and QuietCast™), autopsy saws, and the Stericut® brand of sterile-packed consumables including burs, blades, drills, and K-wires. Additionally, De Soutter offers pulse lavage systems (EcoPulse™) and comprehensive accessories including batteries, chargers, and sterilization containers. ISO 13485 certified, the firm maintains global distribution with offices across Europe, North America, and Australia, serving hospitals, surgical centers, and orthopedic practices.

ViewRay Systems, Inc. is a medical device manufacturer specializing in MRI-guided radiation therapy (MR-gRT) systems for precision cancer treatment. The company's flagship product, MRIdian A3i, integrates diagnostic-quality MRI imaging with radiation delivery and proprietary software to enable real-time soft-tissue visualization, automated beam control, and adaptive dosing. This technology allows radiation oncology centers to reduce treatment volumes, minimize side effects, and improve patient outcomes across multiple cancer types including pancreatic, prostate, lung, liver, breast, and oligometastatic cancers. MRIdian A3i is compatible with existing radiation therapy vaults, facilitating institutional adoption. ViewRay Systems serves university hospitals, community hospitals, private practices, and specialized cancer centers worldwide, supporting program expansion in advanced precision oncology with peer-reviewed clinical evidence demonstrating reduced treatment toxicity and extended survival.

Bearpac Medical manufactures the Passio™ Pump Drainage System, a digital handheld drainage device designed for patients with malignant pleural effusions (MPE). The Passio system represents a novel approach to pleural fluid management, enabling patients to manage their therapy with greater autonomy and comfort in outpatient or home settings. The company offers the Passio Pump as a complete system including a handheld control unit and a proprietary Pleural Catheter Insertion Kit. The device addresses a significant clinical need in oncology and pulmonology by providing convenient, controlled drainage for patients with fluid accumulation in the pleural space—a common complication in advanced malignancy. Bearpac positions the Passio as the first digital handheld system in this category, emphasizing patient comfort, control, and convenience. The company serves hospitals, outpatient facilities, and home care settings treating oncology patients with pleural complications. Product documentation and patient support materials are available in both English and Spanish, indicating attention to diverse patient populations.

BioMedix (Collaborative Care Diagnostics, LLC) is a vascular diagnostics company founded in 2004 specializing in non-invasive physiologic assessment systems for identifying peripheral artery disease (PAD) and managing population health in value-based care settings. The company's primary product line includes PADnet, a flexible and customizable vascular assessment system designed for clinical settings to detect hidden peripheral vascular disease through non-invasive testing, and PADnet Xpress, a portable, rapid screening solution optimized for population health management. BioMedix Xchange is a population health management platform that aggregates test results and patient history for centralized analysis and specialist review. The company enables secure remote transmission of test data and patient information to specialists for interpretation, supporting distributed care models and reducing patient travel burden. PADnet systems are used by podiatrists, primary care physicians, vascular surgeons, cardiologists, and interventional specialists across physician practices, hospitals, and health systems. Products integrate with multi-specialty groups to streamline workflow and improve care coordination between primary physicians and specialists. The company emphasizes training and support for clinical staff to ensure proper testing protocols and diagnostic confidence. Applications include screening high-risk populations (diabetics, smokers, patients over 65), evaluation of intermittent claudication and limb pain, identification of candidates for revascularization procedures, and ongoing management of vascular disease in value-based payment models. The platform supports seamless sharing of diagnostic results across care networks and remote specialist interpretation via secure internet-based systems.

Estone Technology is a global ODM/OEM designer and manufacturer of rugged computing devices for medical, industrial, military, and mission-critical applications. With over 20 years of expertise, the company specializes in custom-built rugged tablet PCs, medical-grade tablets, industrial panel PCs, HMI systems, and embedded computing solutions. Medical product lines include the EN-150 (15.6" AI-enabled tablet for endoscopy, X-ray, and ultrasound image processing), MJ-80 (8" medical rugged tablet), and MD-100 (10.1" medical tablet). Industrial offerings encompass HMI control panels (HMI-70, HMI-1500) and panel PCs (PPC-4107) designed for cleanroom and automated manufacturing environments. Rugged product line includes the UR-100N (10.1" Windows tablet), MS-100A (10.1" Android tablet), and MJ-60 (6" handheld). The company provides full-stack ODM/OEM services: hardware design and PCB engineering, software development (MDM/RDM, application, OS/firmware), device management systems, and AI integration. Estone devices meet MIL-STD-810G/H (environmental durability), MIL-STD-461G (electromagnetic compatibility), and IP67/IP68 waterproofing standards. Additional technologies include RFID integration, CAC/smart card readers, and Ultra-Wideband (UWB) connectivity. Estone operates global offices in the US (Toledo, OH headquarters; Walnut, CA), Europe (Eindhoven, Netherlands), Japan, and China, serving healthcare, industrial automation, logistics, military, and smart agriculture sectors.

Rexmed Health is a medical device original equipment manufacturer (OEM) and contract manufacturer based in El Paso, Texas, with a manufacturing plant in Ciudad Juarez, Mexico. The company specializes in designing, engineering, and manufacturing medical devices for parenteral delivery, infusion therapy, and specialty applications. With over 20 years of experience, Rexmed manufactures products serving ophthalmic surgery, urology, parenteral nutrition, IV therapy, cardiology, airway management, and pain management sectors. Core manufacturing capabilities include fluid delivery sets, infusion pump systems, parenteral bags and configurations, and surgical dispensing coils, produced in certified clean rooms (Class 8 environment). The company holds FDA approval, COFEPRIS (Mexican regulatory) certification, CT-PAT customs certification, and operates under cGMP compliance. Rexmed provides integrated services including process validation (IQ/OQ/PQ), sterilization management, logistics and warehousing, testing services, and master validation planning. The company works with major national and multinational pharmaceutical organizations and emphasizes customized solutions, hand assembly capabilities, special testing, and small-lot production flexibility. Rexmed maintains lean enterprise methodology with six sigma practices and is recognized as a socially responsible company (ESR) by the Mexican Center for Philanthropy. Distribution and logistics partnerships include Silan Medexo (import/export), Doniphan Logistics (distribution center), and PJ Technologies (infusion pump system distribution).

Huestis Machine Corporation, founded in 1920 in Bristol, Rhode Island, is a specialized manufacturer of radiation therapy and diagnostic imaging equipment. The company transitioned from precision industrial machinery to medical device manufacturing in the early 1970s, establishing Huestis Medical to focus on radiotherapy and diagnostic imaging solutions. Huestis is recognized as the world's leading manufacturer of radiation shielding block cutting equipment, with its flagship Styro•former® product introduced in 1975. Following the 1996 acquisition of Cascade X-Ray Inc., the company manufactures the Huestis•Cascade™ radiation therapy simulator—a compact, affordable, and easy-to-install system that requires no floor pit and features Windows-based controls with asymmetrical field wires. The company is ISO 9001 certified and emphasizes cost-effective, reliable performance for community and clinical facilities.

OPKO Health, Inc. is a diversified, publicly traded healthcare company founded in 1991 and based in Miami, Florida. Operating in over 30 countries, OPKO combines three core business segments: diagnostics, pharmaceuticals, and specialty therapeutics. BioReference Laboratories, one of the largest full-service clinical reference laboratories in the United States, serves approximately 11 million patients annually and offers comprehensive genetic testing, specialized diagnostics, and innovative testing platforms including the 4Kscore Test for prostate cancer detection. The pharmaceutical division focuses on research and development of next-generation therapies, particularly multispecific antibodies targeting cancers and infectious diseases. OPKO's marketed therapies include NGENLA™, an FDA-approved human growth hormone for pediatric growth hormone deficiency (partnered with Pfizer and approved in over 40 markets), and RAYALDEE® for secondary hyperparathyroidism treatment. The company maintains strategic partnerships with leading global organizations including Pfizer, Merck, NIH, BARDA, and Duke University, supporting its commitment to advancing innovative therapeutic solutions for serious medical conditions.

CSL Behring LLC is a global biotechnology company specializing in plasma-derived and recombinant biotherapies for rare and serious diseases. The company manufactures and distributes immunoglobulins, clotting factor concentrates for hemophilia and bleeding disorders, therapies for immunodeficiencies, treatments for hereditary angioedema, and Alpha-1 antitrypsin deficiency products. As part of the larger CSL Limited group (founded 1916), CSL Behring operates manufacturing and distribution networks across over 100 countries, with significant recent investment ($1.5 billion) in U.S. plasma-based medicine manufacturing. The company emphasizes quality management, regulatory compliance, and innovation in cell culture reagents and plasma collection infrastructure. CSL's broader portfolio includes CSL Seqirus (vaccines, including influenza and pandemic preparedness), CSL Vifor (iron deficiency and nephrology/dialysis therapies), and CSL Plasma (plasma source plasma collection). With over 25,000 employees globally, the organization focuses on delivering life-saving therapies for bleeding disorders, immune system conditions, and chronic kidney disease.

BTNX Inc. is a leading biotechnology company established in 1996, headquartered in Pickering, Ontario, Canada. Specialized in point-of-care diagnostic solutions, BTNX develops, manufactures, and distributes advanced in-vitro diagnostic tests for laboratories, clinics, and hospitals worldwide. The company's Rapid Response® product line includes rapid diagnostic tests for infectious diseases (COVID-19, influenza), drug screening (fentanyl, xylazine, medetomidine), urinalysis, women's health, and cancer screening. BTNX also manufactures harm reduction testing kits and develops HL7/POCT1-A2 compliant IT systems for test result management. All products are manufactured in ISO 13485:2016 MDSAP-certified facilities and meet CE and FDA standards. The company's diagnostic portfolio reaches over 135 countries and serves healthcare providers, laboratories, and community organizations with both clinical and forensic-use testing solutions.

Applied BioPhotonics Ltd (ABP) is a manufacturer of photobiomodulation therapy (PBT) devices and systems that use light energy to non-invasively stimulate cellular healing and recovery. The company's flagship Mark II system employs LED-based red, infrared, blue, violet, and green wavelengths delivered via flexible, hypoallergenic 3D LightPads to treat tissue-specific conditions. Products are marketed globally under regional brands: LightMD (USA/Europe), AraLight (India/Middle East/Africa), LightDr (Asia/Japan), PetLight (veterinary), and EquineLight (equine). The system features the proprietary LightOS user interface with dozens of tissue-specific treatment protocols, interchangeable pad configurations for different body parts, and precise pulse frequency controls. Clinical applications span pain management, inflammation reduction, musculoskeletal injury recovery, post-operative healing, circulation improvement, fatigue reduction, concussion recovery, and dermatological conditions. ABP serves physicians, hospitals, physical therapists, chiropractors, dermatologists, surgical specialists, dentists, wellness clinics, athletic trainers, and veterinarians. The company holds FDA audit approval, ISO 13485 certification, Taiwan FDA clearance, IEC eye-safety rating, FCC clearance, GMP manufacturing certification, CE marking, and RoHS compliance. Products are non-invasive, non-toxic, non-addictive, and classified as non-pharmaceutical devices. Manufacturing emphasizes medical-grade quality polymers, hypoallergenic materials, and rigorous safety testing.

STARmed America, Inc. is the U.S. subsidiary of South Korean medical device manufacturer STARmed Co., Ltd., established in October 2023. Based in Los Angeles, the company specializes in FDA-cleared radiofrequency ablation (RFA) systems and electrodes for minimally invasive treatment of soft tissue conditions. STARmed offers four RFA generator systems and over ten types of electrodes, including the pioneering thyroid-dedicated RF electrode first developed in 2004. Products are designed for percutaneous and endoluminal ablation applications across thyroid, liver, kidney, lung, bone, biliary, pancreatic, and uterine fibroid conditions. The company currently supports over 120 medical facilities across 36 U.S. states and has trained more than 300 physicians. STARmed provides comprehensive program support including hands-on training, clinical case assistance, reimbursement guidance, and marketing support, with 96% physician satisfaction rates.

BOSS Instruments Ltd. is a family-owned medical device manufacturer based in Gordonsville, Virginia, founded in 1991. The company specializes in German-made surgical instruments and retractor systems serving multiple surgical specialties including ENT, General Surgery, Neurosurgery, Cardiovascular, Orthopedics, Plastics, and Ophthalmology. With a catalog exceeding 20,000 items, BOSS offers advanced retractor systems, forceps, rongeurs, needle holders, and specialty surgical instruments tailored to specific procedural needs. The company distinguishes itself through lifetime quality guarantees, 30-day easy returns, and responsive customer service. BOSS also manufactures innovative single-use surgical lighting solutions including the VersaLight and LightMat products. Their commitment to German craftsmanship and extensive product variety positions them as a comprehensive supplier for surgical instrument procurement across multiple hospital departments.

NeurocarePro is an FDA-registered Class II medical device manufacturer specializing in advanced Pulsed Light Medical Technology (PLMT™) systems for photobiomodulation therapy. The company develops proprietary pulsed red light and near-infrared (NIR) LED therapy systems that utilize multi-spectral, polychromatic light combined with Nogier and Solfeggio frequency algorithms to stimulate multiple cellular targets simultaneously. NeurocarePro's systems are designed to address complex, multi-factorial neurological and musculoskeletal conditions including peripheral neuropathy, chronic pain, cognitive disorders, joint arthritis, wound healing, skin rejuvenation, and athletic recovery. As both a direct manufacturer and clinical provider, NeurocarePro collaborates with medical professionals and researchers globally to develop and refine products. The company offers complete turnkey solutions with protocol assistance, clinical implementation support, and 100% warranty coverage. Products are available through professional healthcare channels and consumer direct purchase options.

MediBeacon Inc. is a medical technology company specializing in fluorescent tracer agents and transdermal detection technology for non-invasive physiological monitoring. The company's proprietary platform enables real-time measurement and monitoring of vital organ function through biocompatible fluorescent agents that are sensed through the skin via transdermal optical sensors. Primary clinical focus areas include nephrology (kidney function assessment via transdermal GFR measurement), gastroenterology (gut barrier permeability assessment), ophthalmology (fluorescent angiography for retinal vasculature visualization), and surgical applications (intraoperative visualization and identification of anatomical structures). MediBeacon's Transdermal GFR (TGFR) System received FDA PMA approval (P230019) and CE Mark for human clinical use. The company serves leading academic medical centers, research institutes, contract research organizations (CROs), and pharmaceutical companies globally for both preclinical research and clinical applications. MediBeacon maintains offices in St. Louis, Missouri (USA), Mannheim, Germany, and partnerships in Greater China through Huadong Medicine Co., Ltd.

Eufoton S.r.l. is an Italian manufacturer of innovative diode laser and LED-based pulsed light systems for medical, dental, and aesthetic applications. Founded in 1997 and ISO 13485 certified, the company designs and produces portable laser solutions utilizing gallium arsenide semiconductors with minimal maintenance requirements and no consumables. The flagship LASEmaR™ product series serves dermatology, plastic surgery, gynecology, phlebology, dentistry, and veterinary medicine globally. Core offerings include the Endolift® non-surgical laser-assisted lifting technology and specialized handpieces for hair removal, vascular treatments, and therapeutic applications. Eufoton distributes across Europe, Middle East, Asia, and South America, maintaining CE marking compliance and quality standards. The company supports practitioners through comprehensive training programs (ELEA—Eufoton Laser Academy) and hosts specialized events for surgical techniques.

NEO Science, headquartered in Glendale, California, is a leading distributor and innovator in health optimization technologies, specializing in advanced photobiomodulation (red/infrared light therapy) and whole-body cryotherapy equipment. Founded by Robin Kuehne, a 15+ year industry pioneer who introduced cryotherapy to the US, NEO Science designs and distributes cutting-edge wellness devices for spas, recovery centers, chiropractic clinics, and medical wellness facilities. The company's product portfolio includes the NEO Light Bed (full-body photobiomodulation system with customizable light modes), NEO Pod and NEO Cool (targeted cryotherapy units), and integration with Starpool premium wellness systems. NEO Science emphasizes touchless technology, non-invasive treatment protocols, and proven clinical benefits including muscle recovery, cellular energy production, collagen stimulation, wound healing acceleration, and anti-aging outcomes. B2B-focused, offering white-glove setup, financing, custom branding support, and training to help wellness businesses unlock new revenue streams. Recognized as a 2025 Inc. 5000 fastest-growing company and 2025 CINA Best Customer Service Award winner.